MediumEndocrinologyType 2 diabetes with chronic kidney diseaseau-amcau-racp
A 68-year-old man with type 2 diabetes and chronic kidney disease (eGFR 40 mL/min/1.73 m²) is reviewed in general practice. He is on metformin and an ACE inhibitor. His HbA1c is 7.8%. According to Australian guidelines, which additional class of glucose-lowering agent has the strongest evidence for renal and cardiovascular benefit in this setting?